The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive
therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to
Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.